Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 22, Issue 8, 2009, Pages 672-687

  Erez, Offer ^a   Gotsch, Francesca ^a   Mazaki Tovi, Shali ^a   Vaisbuch, Edi ^a   Kusanovic, Juan Pedro ^a   Kim, Chong Jai ^a,b   Chaiworapongsa, Tinnakorn ^a   Hoppensteadt, Deborah ^c   Fareed, Jawed ^c   Than, Nandor G ^a   Nhan Chang, Chia Ling ^a   Yeo, Lami ^a   Pacora, Percy ^a   Mazor, Moshe ^d   Hassan, Sonia S ^a   Mittal, Pooja ^a   Romero, Roberto ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Abruption; Preeclampsia; Pregnancy; Prothrombin fragments 1 2; Soluble CD40L; Thrombinantithrombin complexes

Indexed keywords

ANTITHROMBIN III; CD40 LIGAND; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AMNIOCENTESIS; AMNION FLUID; AMNION FLUID ANALYSIS; ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; FETUS DEATH; FUNCTIONAL STATUS; HEMOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MATERNAL PLASMA; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLUTIO PLACENTAE; THROMBOCYTE ACTIVATION;

ADULT; AMNIOTIC FLUID; ANTITHROMBIN III; CD40 LIGAND; CROSS-SECTIONAL STUDIES; FEMALE; FETAL DEATH; HUMANS; LIPOPROTEINS; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PLATELET ACTIVATION; PRE-ECLAMPSIA; PREGNANCY; PROTEIN PRECURSORS; PROTHROMBIN; THROMBIN; THROMBOPLASTIN;

EID: 70350660636     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050902853117     Document Type: Article

References (165)

1. Romero R, Copel JA, Hobbins JC. Intrauterine fetal demise and hemostatic failure: the fetal death syndrome. Clin Obstet Gynecol 1985;28:24-31.
2. Weiner AE, Reid DE, Roby CC, Diamond LK. Coagulation defects with intrauterine death from Rh isosensitization. Am J Obstet Gynecol 1950;60:1015-1022.
3. Reid DE, Weiner AE, Roby CC, Diamond LK. Maternal afibrinogenemia associated with long-standing intrauterine fetal death. Am J Obstet Gynecol 1953;66:500-506.
4. Pritchard JA, Ratnoff OD. Studies of fibrinogen and other hemostatic factors in women with intrauterine death and delayed delivery. Surg Gynecol Obstet 1955;101:467-477.
5. Tricomi V, Kohl SG. [Fetal death in utero.]. Am J Obstet Gynecol 1957;74:1092-1097.
6. Pritchard JA. Fetal death in utero. Obstet Gynecol 1959;14: 573-580.
7. de Boer K, ten Cate JW, Sturk A, Borm JJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989;160:95-100.
8. Yuen PM, Yin JA, Lao TT. Fibrinopeptide A levels in maternal and newborn plasma. Eur J Obstet Gynecol Reprod Biol 1989;30:239-244.
9. Sorensen JD, Secher NJ, Jespersen J. Perturbed (procoagulant) endothelium and deviations within the fibrinolytic system during the third trimester of normal pregnancy. A possible link to placental function. Acta Obstet Gynecol Scand 1995;74:257-261.
10. Walker MC, Garner PR, Keely EJ, Rock GA, Reis MD. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997;177:162-169.
11. Bellart J, Gilabert R, Miralles RM, Monasterio J, Cabero L. Endothelial cell markers and fibrinopeptide A to D-dimer ratio as a measure of coagulation and fibrinolysis balance in normal pregnancy. Gynecol Obstet Invest 1998;46:17-21.
12. Lockwood CJ, Krikun G, Schatz F. The decidua regulates hemostasis in human endometrium. Semin Reprod Endocrinol 1999;17:45-51.
13. Lockwood CJ, Krikun G, Schatz F. Decidual cell-expressed tissue factor maintains hemostasis in human endometrium. Ann N.Y Acad Sci 2001;943:77-88.
14. Kuczynski J, Uszynski W, Zekanowska E, Soszka T, Uszynski M. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in the placenta and myometrium. Eur J Obstet Gynecol Reprod Biol 2002;105:15-19.
15. Erlich J, Parry GC, Fearns C, MullerM, Carmeliet P, Luther T, Mackman N. Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation. Proc Natl Acad Sci U.S.A 1999;96:8138-8143.
16. Creter D. Amnioplastin: new reagent for coagulation tests. Lancet 1977;2:251.
17. Omsjo IH, Oian P, Maltau JM, Osterud B. Thromboplastin activity in amniotic fluid. Gynecol Obstet Invest 1985;19:1-5.
18. Lockwood CJ, Bach R, Guha A, Zhou XD, Miller WA, Nemerson Y. Amniotic fluid contains tissue factor, a potent initiator of coagulation. Am J Obstet Gynecol 1991; 165:1335-1341.
19. Uszynski M, Zekanowska E, Uszynski W, Kuczynski J. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in amniotic fluid and blood plasma: implications for the mechanism of amniotic fluid embolism. Eur J Obstet Gynecol Reprod Biol 2001;95:163-166.
20. Holmes VA, Wallace JM. Haemostasis in normal pregnancy: a balancing act? Biochem Soc Trans 2005;33:428-432.
21. Chaiworapongsa T, Espinoza J, Yoshimatsu J, Kim YM, Bujold E, Edwin S, Yoon BH, Romero R. Activation of coagulation system in preterm labor and preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2002; 11:368-373. (Pubitemid 34836886)
22. Reinthaller A, Mursch-Edlmayr G, Tatra G. Thrombinantithrombin III complex levels in normal pregnancy with hypertensive disorders and after delivery. Br J Obstet Gynaecol 1990;97:506-510.
23. Uszynski M. Generation of thrombin in blood plasma of non-pregnant and pregnant women studied through concentration of thrombin-antithrombin III complexes. Eur J Obstet Gynecol Reprod Biol 1997;75:127-131.
24. Reber G, Amiral J, de MP. Modified antithrombin III levels during normal pregnancy and relationship with prothrombin fragment F1 + 2 and thrombin-antithrombin complexes. Thromb Res 1998;91:45-47.
25. Andersson T, Lorentzen B, Hogdahl H, Clausen T, Mowinckel MC, Abildgaard U. Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res 1996;82:109-117.
26. VanWijk MJ, Boer K, Berckmans RJ, Meijers JC, van der Post JA, Sturk A, Vanbavel E, Nieuwland R. Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Thromb Haemost 2002;88:415-420.
27. Kobayashi T, Sumimoto K, Tokunaga N, Sugimura M, Nishiguchi T, Kanayama N, Terao T. Coagulation index to distinguish severe preeclampsia from normal pregnancy. Semin Thromb Hemost 2002;28:495-500.
28. Hayashi M, Numaguchi M, Ohkubo N, Yaoi Y. Blood macrophage colony-stimulating factor and thrombinantithrombin III complex concentrations in pregnancy and preeclampsia. Am J Med Sci 1998;315:251-257.
29. Hayashi M, Inoue T, Hoshimoto K, Negishi H, Ohkura T, Inaba N. Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and pre-eclampsia. Eur J Haematol 2002;69:297-302. (Pubitemid 36005818)
30. Chaiworapongsa T, Yoshimatsu J, Espinoza J, Kim YM, Berman S, Edwin S, Yoon BH, Romero R. Evidence of in vivo generation of thrombin in patients with small-forgestational- age fetuses and pre-eclampsia. J Matern Fetal Neonatal Med 2002;11:362-367.
31. Kobayashi T, Terao T. Preeclampsia as chronic disseminated intravascular coagulation. Study of two parameters: thrombin-antithrombin III complex and D-dimers. Gynecol Obstet Invest 1987;24:170-178.
32. Kobayashi T, Tokunaga N, Sugimura M, Suzuki K, Kanayama N, Nishiguchi T, Terao T. Coagulation/fibrinolysis disorder in patients with severe preeclampsia. Semin Thromb Hemost 1999;25:451-454.
33. Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset PM, Wisloff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand 1999;78:191-197.
34. Hayashi M, Ohkura T. Elevated levels of serum macrophage colony-stimulating factor in normotensive pregnancies complicated by intrauterine fetal growth restriction. Exp Hematol 2002;30:388-393.
35. Ballard HS, Marcus AJ. Primary and secondary platelet aggregation in uraemia. Scand J Haematol 1972;9:198-203.
36. ElovitzMA, Baron J, PhillippeM. The role of thrombin in preterm parturition. Am J Obstet Gynecol 2001;185:1059-1063.
37. Rosen T, Kuczynski E, O'Neill LM, Funai EF, Lockwood CJ. Plasma levels of thrombin-antithrombin complexes predict preterm premature rupture of the fetal membranes. J Matern Fetal Med 2001;10:297-300.
38. Gonzalez RP, Gomez RM, Castro RS, Nien JK, Merino PO, Etchegaray AB, Carstens MR, Medina LH, Viviani PG, Rojas IT. [A national birth weight distribution curve according to gestational age in chile from 1993 to 2000]. Rev Med Chil 2004;132:1155-1165.
39. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002;99:159-167.
40. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1330.
41. Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost 2007;5:604-606.
42. Redline RW, Heller D, Keating S, Kingdom J. Placental diagnostic criteria and clinical correlation-a workshop report. Placenta 2005;26 (Suppl A):S114-S117.
43. Patel JV, Lim HS, Nadar S, Tayebjee M, Hughes EA, Lip GY. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens 2006;24:117-121.
44. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity Creactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007;38:1229-1237.
45. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001;12:74-82.
46. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 2005;25:2428-2434.
47. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
48. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;98:1047-1054.
49. Saleh AA, Bottoms SF, Farag AM, Dombrowski MP, Welch RA, Norman G, Mammen EF. Markers for endothelial injury, clotting and platelet activation in preeclampsia. Arch Gynecol Obstet 1992;251:105-110.
50. Leiberman JR, Hagay ZJ, Mazor M, Aharon M, Nathan I, Dvilansky A. Plasma and urine beta-thromboglobulin in severe preeclampsia. Arch Gynecol Obstet 1988;243:165-168.
51. Holthe MR, Lyberg T, Staff AC, Berge LN. Leukocyteplatelet interaction in pregnancies complicated with preeclampsia. Platelets 2005;16:91-97.
52. Lok CA, Nieuwland R, Sturk A, Hau CM, Boer K, Vanbavel E, Vanderpost JA. Microparticle-associated P-selectin re- flects platelet activation in preeclampsia. Platelets 2007;18:68-72.
53. Tomer A. Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents 2004;18:172-177.
54. Yoneyama Y, Suzuki S, Sawa R, Kiyokawa Y, Power GG, Araki T. Plasma adenosine levels and P-selectin expression on platelets in preeclampsia. Obstet Gynecol 2001;97:366-370. (Pubitemid 32184694)
55. Bar J, Zosmer A, Hod M, Elder MG, Sullivan MH. The regulation of platelet aggregation in vitro by interleukin- 1beta and tumor necrosis factor-alpha: changes in pregnancy and in pre-eclampsia. Thromb Haemost 1997;78:1255-1261.
56. Bagamery K, Landau R, Kvell K, Graham J. Different platelet activation levels in non-pregnant, normotensive pregnant, pregnancy-induced hypertensive and preeclamptic women. A pilot study of flow cytometric analysis. Eur J Obstet Gynecol Reprod Biol 2005;121:117-118.
57. Harlow FH, Brown MA, Brighton TA, Smith SL, Trickett AE, Kwan YL, Davis GK. Platelet activation in the hypertensive disorders of pregnancy. Am J Obstet Gynecol 2002; 187:688-695.
58. Missfelder-Lobos H, Teran E, Lees C, Albaiges G, Nicolaides KH. Platelet changes and subsequent development of pre-eclampsia and fetal growth restriction in women with abnormal uterine artery Doppler screening. Ultrasound Obstet Gynecol 2002;19:443-448.
59. Felfernig-Boehm D, Salat A, Vogl SE, Murabito M, Felfernig M, Schmidt D, Mittlboeck M, Husslein P, Mueller MR. Early detection of preeclampsia by determination of platelet aggregability. Thromb Res 2000;98:139-146.
60. Myatt L, Miodovnik M. Prediction of preeclampsia. Semin Perinatol 1999;23:45-57.
61. Konijnenberg A, van der Post JA, Mol BW, Schaap MC, Lazarov R, Bleker OP, Boer K, Sturk A. Can flow cytometric detection of platelet activation early in pregnancy predict the occurrence of preeclampsia? A prospective study. Am J Obstet Gynecol 1997;177:434-442.
62. Bodis J, Torok A, Tinneberg HR. Hypothesis of preeclampsia requires inclusion of the role of platelets. Am J Obstet Gynecol 1997;177:243-244.
63. Konijnenberg A, Stokkers EW, van der Post JA, Schaap MC, Boer K, Bleker OP, Sturk A. Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol 1997;176:461-469.
64. Ahlawat S, Pati HP, Bhatla N, Fatima L, Mittal S. Plasma platelet aggregating factor and platelet aggregation studies in pre-eclampsia. Acta Obstet Gynecol Scand 1996;75:428-431.
65. Halim A, Kanayama N, el ME, Nakashima A, Bhuiyan AB, Khatun S, Terao T. Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Am J Obstet Gynecol 1996;174:272-277.
66. Janes SL, Kyle PM, Redman C, Goodall AH. Flow cytometric detection of activated platelets in pregnant women prior to the development of pre-eclampsia. Thromb Haemost 1995;74:1059-1063.
67. Janes SL, Goodall AH. Flow cytometric detection of circulating activated platelets and platelet hyper-responsiveness in pre-eclampsia and pregnancy. Clin Sci (Lond) 1994;86: 731-739.
68. Hutt R, Ogunniyi SO, Sullivan MH, Elder MG. Increased platelet volume and aggregation precede the onset of preeclampsia. Obstet Gynecol 1994;83:146-149.
69. Norris LA, Gleeson N, Sheppard BL, Bonnar J. Whole blood platelet aggregation in moderate and severe preeclampsia. Br J Obstet Gynaecol 1993;100:684-688.
70. Louden KA, Broughton PF, Heptinstall S, Fox SC, Mitchell JR, Symonds EM. Platelet reactivity and serum thromboxane B2 production in whole blood in gestational hypertension and pre-eclampsia. Br J Obstet Gynaecol 1991;98:1239-1244.
71. Pekonen F, Rasi V, Ammala M, Viinikka L, Ylikorkala O. Platelet function and coagulation in normal and preeclamptic pregnancy. Thromb Res 1986;43:553-560.
72. Romero R, Snyder E, Scott D, Oyarzun E, Hobbins JC, Duffy TP. Beta-thromboglobulin during normal pregnancy, labor, and puerperium. Am J Perinatol 1988;5:109-112.
73. Hagay ZJ, Leiberman JR, Mazor M, Aharon M, Dvilansky A. [Plasma and urinary beta-thromboglobulin as indicators of platelet activation in pre-eclampsia]. Harefuah 1988;114: 427-429.
74. Karalis I, Nadar SK, Al YE, Blann AD, Lip GY. Platelet activation in pregnancy-induced hypertension. Thromb Res 2005;116:377-383.
75. Yoneyama Y, Suzuki S, Sawa R, Miura A, Doi D, Otsubo Y, Araki T. Plasma nitric oxide levels and the expression of Pselectin on platelets in preeclampsia. Am J Obstet Gynecol 2002;187:676-680.
76. Erez O, Hallak M, Luber A, Maymon E, Mazor M, Tomer A. Platelets Activation Marker as Predictor of Severe Preeclampsia in Patients with History of Preeclampsia. Am J Obstet Gynecol 2001;185:S175.
77. Ballegeer VC, Spitz B, De Baene LA, Van Assche AF, Hidajat M, Criel AM. Platelet activation and vascular damage in gestational hypertension. Am J Obstet Gynecol 1992;166:629-633.
78. Ayhan A, Akkok E, Urman B, Yarali H, Dundar S, Kirazli S. Beta-thromboglobulin and platelet factor 4 levels in pregnancy and preeclampsia. Gynecol Obstet Invest 1990;30:12-14.
79. Csaicsich P, Deutinger J, Tatra G. Platelet specific proteins (beta-thromboglobulin and platelet factor 4) in normal pregnancy and in pregnancy complicated by preeclampsia. Arch Gynecol Obstet 1989;244:91-95.
80. Socol ML, Weiner CP, Louis G, Rehnberg K, Rossi EC. Platelet activation in preeclampsia. Am J Obstet Gynecol 1985;151:494-497.
81. Arocha-PinangoCL,OjedaA,LopezG,GarciaL,Linares J. betathromboglobulin (beta-TG) and platelet factor 4 (PF4) in obstetrical cases. Acta Obstet Gynecol Scand 1985;64:115-120.
82. Alacacioglu I, Ozcan MA, Piskin O, Yuksel F, Alacacioglu A, Demirkan F, Ozsan HG, Polat M, Ozgenc Y, Undar B. Increased concentration of soluble CD40 ligand in preeclampsia. Clin Appl Thromb Hemost 2007;13:201-205.
83. Laskowska M, Laskowska K, Leszczynska-Gorzelak B, Oleszczuk J. sCD40 ligand determined in maternal and umbilical cord blood in pregnancies complicated by preeclampsia with and without intrauterine growth retardation. Gynecol Obstet Invest 2007;64:8-13.
84. Mellembakken JR, Solum NO, Ueland T, Videm V, Aukrust P. Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia-possible role of platelet activation. Thromb Haemost 2001;86:1272-1276.
85. Oron G, Ben-Haroush A, Hod M, Orvieto R, Bar J. Serumsoluble CD40 ligand in normal pregnancy and in preeclampsia. Obstet Gynecol 2006;107:896-900.
86. Erez O, Romero R, Hoppensteadt D, Fareed J, Chaiworapongsa T, Kusanovic JP, Mazaki-Tovi S, Gotsch F, Than NG, Vaisbuch E, et al. Premature labor: a state of platelet activation? J Perinat Med 2008;36:377-387.
87. Holvoet P, Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol 1997;8:320-328.
88. Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS. Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation. Heart 2008;94:e21.
89. Maroney SA, Haberichter SL, Friese P, Collins ML, Ferrel JP, Dale GL, Mast AE. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 2007;109:1931-1937.
90. Sobocka MB, Sobocki T, Babinska A, Hartwig JH, Li M, Ehrlich YH, Kornecki E. Signaling pathways of the F11 receptor (F11R; a.k.a. JAM-1, JAM-A) in human platelets: F11R dimerization, phosphorylation and complex formation with the integrin GPIIIa. J Recept Signal Transduct Res 2004;24:85-105.
91. Weiss HJ, Lages B. Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity-a comparison with Scott syndrome. Blood 1997;89:1599-1611.
92. Banno Y, Nakashima S, Ohzawa M, Nozawa Y. Differential translocation of phospholipase C isozymes to integrinmediated cytoskeletal complexes in thrombin-stimulated human platelets. J Biol Chem 1996;271:14989-14994.
93. Miller GJ. Lipoproteins and the haemostatic system in atherothrombotic disorders. Baillieres Clin Haematol 1994; 7:713-732.
94. Esumi N, Todo S, Imashuku S. Platelet aggregating activity mediated by thrombin generation in the NCG human neuroblastoma cell line. Cancer Res 1987;47:2129-2135.
95. Yoshida K, Kimura H. Presence of calmodulin in human platelet cytoskeletons and its concentration change upon activation of platelets. Biochim Biophys Acta 1984;801:290-297.
96. Sood R, Zogg M, Westrick RJ, Guo YH, Kerschen EJ, Girardi G, Salmon JE, Coughlin SR, Weiler H. Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. J Exp Med 2007;204:1049-1056.
97. Hoffman M, Monroe DM, III. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965.
98. Hung DT, Vu TK, Wheaton VI, Ishii K, Coughlin SR. Cloned platelet thrombin receptor is necessary for thrombininduced platelet activation. J Clin Invest 1992;89:1350-1353.
99. Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol 2006;546:142-147.
100. Lisman T, Weeterings C, de Groot PG. Platelet aggregation: involvement of thrombin and fibrin(ogen). Front Biosci 2005;10:2504-2517.
101. Keuren JF, Wielders SJ, Ulrichts H, Hackeng T, Heemskerk JW, Deckmyn H, Bevers EM, Lindhout T. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol 2005;25:1499-1505.
102. Lova P, Campus F, Lombardi R, Cattaneo M, Sinigaglia F, Balduini C, Torti M. Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)- independent activation of platelet Rap1B by thrombin. J Biol Chem 2004;279:25299-25306.
103. Dubois C, Steiner B, Meyer Reigner SC. Contribution of PAR-1, PAR-4 and GPIbalpha in intracellular signaling leading to the cleavage of the beta3 cytoplasmic domain during thrombin-induced platelet aggregation. Thromb Haemost 2004;91:733-742.
104. Soslau G, Class R, Morgan DA, Foster C, Lord ST, Marchese P, Ruggeri ZM. Unique pathway of thrombininduced platelet aggregation mediated by glycoprotein Ib. J Biol Chem 2001;276:21173-21183.
105. Dicker IB, Pedicord DL, Seiffert DA, Jamieson GA, Greco NJ. Both the high affinity thrombin receptor (GPIb-IX-V) and GPIIb/IIIa are implicated in expression of thrombininduced platelet procoagulant activity. Thromb Haemost 2001;86:1065-1069.
106. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De CR. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001;276:4692-4698.
107. Monkovic DD, Tracy PB. Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem 1990;265:17132-17140.
108. Ahmad SS, Rawala-Sheikh R, Walsh PN. Comparative interactions of factor IX and factor IXa with human platelets. J Biol Chem 1989;264:3244-3251.
109. Ahmad SS, Rawala-Sheikh R, Ashby B, Walsh PN. Platelet receptor-mediated factor X activation by factor IXa. Highaffinity factor IXa receptors induced by factor VIII are deficient on platelets in Scott syndrome. J Clin Invest 1989;84:824-828.
110. Ahmad SS, Rawala-Sheikh R, Walsh PN. Platelet receptor occupancy with factor IXa promotes factor X activation. J Biol Chem 1989;264:20012-20016.
111. Rawala-Sheikh R, Ahmad SS, Ashby B, Walsh PN. Kinetics of coagulation factor X activation by platelet-bound factor IXa. Biochemistry 1990;29:2606-2611.
112. Sinosich MJ, Wolf JP, Williams RF, Hodgen GD. RU 486 mediated leukocytic inflammatory reaction at the uteroplacental interface. Asia Oceania J Obstet Gynaecol 1989; 15:375-381.
113. Richani K, Romero R, Soto E, Espinoza J, Nien JK, Chaiworapongsa T, Refuerzo J, Blackwell S, Edwin SS, Santolaya-Forgas J, et al. Unexplained intrauterine fetal death is accompanied by activation of complement. J Perinat Med 2005;33:296-305.
114. Ferrer-Lopez P, Renesto P, Schattner M, Bassot S, Laurent P, Chignard M. Activation of human platelets by C5astimulated neutrophils: a role for cathepsin G. Am J Physiol 1990;258:C1100-C1107.
115. Schjetlein R, Haugen G, Wisloff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand 1997;76:541-546.
116. Sood R, Sholl L, Isermann B, Zogg M, Coughlin SR, Weiler H. Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin. Blood 2008;112:585-591.
117. Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood 2006;107:3173-3180.
118. Aharon A, Brenner B, Katz T, Miyagi Y, Lanir N. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. Thromb Haemost 2004;92:776-786.
119. Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, Mackman N, Weiler H. The thrombomodulinprotein C system is essential for the maintenance of pregnancy. Nat Med 2003;9:331-337.
120. Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost 2003;29:175-184.
121. Butenas S, Brummel-Ziedins KE, Mann KG. Real human tissue factor. FASEB J 2006;20:A47.
122. Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG. Tissue factor in thrombosis and hemorrhage. Surgery 2007; 142:S2-14.
123. Osterud B. Cellular interactions in tissue factor expression by blood monocytes. Blood Coagul Fibrinolysis 1995;6 Suppl 1:S20-S25.
124. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T, Shiku H. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1995;73:10-14.
125. Balasubramanian V, Grabowski E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002;100:2787-2792.
126. Balasubramanian V, Vele O, Nemerson Y. Local shear conditions and platelet aggregates regulate the incorporation and activity of circulating tissue factor in ex-vivo thrombi. Thromb Haemost 2002;88:822-826.
127. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004;104:3190-3197.
128. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami- Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005;105:2764-2770.
129. Schneider C. The active principle of placental toxin:thromboplastin its inactivator in blood: antithromboplastin. Am J Physiol 1947;149:123.
130. Erez O, Hoppensteadt D, Than NG, Fareed J, Mazaki-Tovi S, Espinoza J, Chaiworapongsa T, Yoon BH, Hassan SS, Gotsch F, et al. Tissue Factor and its Natural Inhibitor in Preeclampsia and SGA. J Matern Fetal Neonatal Med 2008;12:855-869.
131. Bellart J, Gilabert R, Angles A, Piera V, Miralles RM, Monasterio J, Cabero L. Tissue factor levels and high ratio of fibrinopeptide A:D-dimer as a measure of endothelial procoagulant disorder in pre-eclampsia. Br J Obstet Gynaecol 1999;106:594-597.
132. HOWIE BO. Intra-uterine foetal death with defective maternal blood-clotting mechanism. Proc R Soc Med 1956;49:93-96.
133. DeValera E. Abruptio placentae. Am J Obstet Gynecol 1968;100:599-606.
134. Sher G, Statland BE. Abruptio placentae with coagulopathy: a rational basis for management. Clin Obstet Gynecol 1985;28:15-23.
135. Oyelese Y, Ananth CV. Placental abruption. Obstet Gynecol 2006;108:1005-1016.
136. Beller FK, Uszynski M. Disseminated intravascular coagulation in pregnancy. Clin Obstet Gynecol 1974;17:250-278.
137. Boulton FE, Letsky E. Obstetric haemorrhage: causes and management. Clin Haematol 1985;14:683-728.
138. Finley BE. Acute coagulopathy in pregnancy. Med Clin North Am 1989;73:723-743.
139. Parasnis H, Raje B, Hinduja IN. Relevance of plasma fibrinogen estimation in obstetric complications. J Postgrad Med 1992;38:183-185.
140. Thomson AJ, Greer IA. Non-haemorrhagic obstetric shock. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:19-41.
141. Awwad JT, Azar GB, Seoud MA, Mroueh AM, Karam KS. High-velocity penetrating wounds of the gravid uterus: review of 16 years of civil war. Obstet Gynecol 1994;83: 259-264.
142. Enakpene CA, Omigbodun AO, Arowojolu AO. Perinatal mortality following umbilical cord prolapse. Int J Gynaecol Obstet 2006;95:44-45.
143. Aagaard-Tillery KM, Holmgren C, Lacoursiere DY, Houssain S, Bloebaum L, Satterfield R, Branch DW, Varner MW. Factors associated with nonanomalous stillbirths: the Utah Stillbirth Database 1992-2002. Am J Obstet Gynecol 2006;194:849-854.
144. Korteweg FJ, Gordijn SJ, Timmer A, Holm JP, Ravise JM, Erwich JJ. A placental cause of intra-uterine fetal death depends on the perinatal mortality classification system used. Placenta 2008;29:71-80.
145. Copper RL, Goldenberg RL, DuBard MB, Davis RO. Risk factors for fetal death in white, black, and Hispanic women. Collaborative Group on Preterm Birth Prevention. Obstet Gynecol 1994;84:490-495.
146. Lammer EJ, Brown LE, Anderka MT, Guyer B. Classification and analysis of fetal deaths in Massachusetts. JAMA 1989;261:1757-1762.
147. Menghrajani P, Osterheld MC. Significance of hemorrhagic endovasculitis in placentae from stillbirths. Pathol Res Pract 2008;204:389-394.
148. ACOG Committee Opinion No. 383: Evaluation of stillbirths and neonatal deaths. Obstet Gynecol 2007;110:963-966.
149. Corabian P, Scott NA, Lane C, Guyon G. Guidelines for investigating stillbirths: an update of a systematic review. J Obstet Gynaecol Can 2007;29:560-567.
150. Marchetti D, Belviso M, Marino M, Gaudio R. Evaluation of the placenta in a stillborn fetus to estimate the time of death. Am J Forensic Med Pathol 2007;28:38-43.
151. Pasupathy D, Smith GC. The analysis of factors predicting antepartum stillbirth. Minerva Ginecol 2005;57:397-410.
152. Sander CM, Gilliland D, Richardson A, Foley KM, Fredericks J. Stillbirths with placental hemorrhagic endovasculitis: a morphologic assessment with clinical implications. Arch Pathol Lab Med 2005;129:632-638.
153. Pierce BT, Martin LS, Hume RF Jr. Calhoun BC, Muir- Padilla J, Salafia CM. Relationship between the extent of histologic villous mineralization and stillbirth in aneuploid and euploid fetuses. J Soc Gynecol Investig 2002;9:290-293.
154. Magee JF. Investigation of stillbirth. Pediatr Dev Pathol 2001;4:1-22.
155. Kraus FT, Acheen VI. Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Hum Pathol 1999;30:759-769.
156. Incerpi MH, Miller DA, Samadi R, Settlage RH, Goodwin TM. Stillbirth evaluation: what tests are needed? Am J Obstet Gynecol 1998;178:1121-1125.
157. Adelson P, Spurrett B, Trudinger B, Frommer M. A New South Wales population-based study of stillbirths weighing 2,500 g or more. Aust N.Z J Obstet Gynaecol 1993;33:166-173.
158. Gruenberger W, Gerstner GJ. The causes of antepartum fetal death: a clinico-pathological study. Clin Exp Obstet Gynecol 1980;7:210-214.
159. Bendon RW. Review of some causes of stillbirth. Pediatr Dev Pathol 2001;4:517-531.
160. Arias F, Romero R, Joist H, Kraus FT. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med 1998;7:277-286.
161. Cartlidge PH, Dawson AT, Stewart JH, Vujanic GM. Value and quality of perinatal and infant postmortem examinations: cohort analysis of 400 consecutive deaths. BMJ 1995; 310:155-158.
162. Fretts RC, Boyd ME, Usher RH, Usher HA. The changing pattern of fetal death, 1961-1988. Obstet Gynecol 1992; 79:35-39.
163. Pauli RM, Reiser CA. Wisconsin Stillbirth Service Program: II. Analysis of diagnoses and diagnostic categories in the first 1,000 referrals. Am J Med Genet 1994;50:135-153.
164. Faye-Petersen OM, Guinn DA, Wenstrom KD. Value of perinatal autopsy. Obstet Gynecol 1999;94:915-920.
165. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002;100:148-152.